Search results
Results from the WOW.Com Content Network
In medicine, proton therapy, or proton radiotherapy, is a type of particle therapy that uses a beam of protons to irradiate diseased tissue, most often to treat cancer.The chief advantage of proton therapy over other types of external beam radiotherapy is that the dose of protons is deposited over a narrow range of depth; hence in minimal entry, exit, or scattered radiation dose to healthy ...
Proton beam therapy has been shown to be just as effective as traditional chemotherapy, with fewer side effects and less treatment time.
Tiotropium was patented in 1989, and approved for medical use in 2002. [12] It is on the World Health Organization's List of Essential Medicines. [13] In 2022, it was the 154th most commonly prescribed medication in the United States, with more than 3 million prescriptions. [14] [15]
Cancer cells can also cause defects in the cellular pathways of apoptosis (programmed cell death). As most chemotherapy drugs kill cancer cells in this manner, defective apoptosis allows survival of these cells, making them resistant. Many chemotherapy drugs also cause DNA damage, which can be repaired by enzymes in the cell that carry out DNA ...
Cancer treatments are a wide range of treatments available for the many different types of cancer, with each cancer type needing its own specific treatment. [1] Treatments can include surgery, chemotherapy, radiation therapy, hormonal therapy, targeted therapy including small-molecule drugs or monoclonal antibodies, [2] and PARP inhibitors such as olaparib. [3]
The Mayo Clinic Cancer Center is one of the oldest NCI-designated cancer centers in the United States, having first been designated in 1973. [3] The main location of the Mayo Clinic is in Rochester, MN. Campuses in Arizona and Florida opened later and became part of the Mayo Clinic Cancer Center in 2003. [4] [5]
Oncology is a branch of medicine that deals with the study, treatment, diagnosis, and prevention of cancer.A medical professional who practices oncology is an oncologist. [1]
In a clinical trial of 50 patients, combination of olaparib and temozolomide in relapsed small-cell lung cancer yielded an overall response rate of 41.7%, median progression-free survival 4.2 months, and overall survival was 8.5 months. [64] Lurbinectedin showed increased overall survival rate in relapsed small cell lung cancer in a trial. [65]